EurekAlert! -
21 Feb 2020 07:00
(University of Texas M. D. Anderson Cancer Center) Comprehensive profiling of tumor samples taken from patients with osteosarcoma shows that multiple factors contribute to the traditionally poor responses observed from treatment with immune checkpoint inhibitors, according to new research from The University of Texas MD Anderson Cancer Center.
Share this Article
Comment on this Article
Please to comment